Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Importance of Exercise Training Therapy Timing With Regard to Cardiotoxicity and Patient Preference in Early Breast Cancer and Lymphoma Patients Undergoing Adjuvant Chemotherapy

NCT03850171 is registered in ClinicalTrials.gov with Insel Gruppe AG, University Hospital Bern as lead sponsor.

NCT NCT03850171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03850171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Importance of Exercise Training Therapy Timing With Regard to Cardiotoxicity and Patient Preference in Early Breast Cancer and Lymphoma Patients Undergoing Adjuvant Chemotherapy
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Phase
Not applicable
Overall status
Terminated
Start date
May 1, 2019
Completion date
January 31, 2023
Enrollment
57 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

anthracyclines, breast neoplasm female, cardiotoxicity, lymphoma, physical activity